ITeos Therapeutics

iTeos Therapeutics is active in Immunotherapy domain and focused on the validation and development of "immunomodulatory" molecules with the potential to act in synergy with other cancer therapies to restore immune activity against tumors.

The company's portfolio consists of proprietary products targeting IDO1, A2A, TIGIT in inflamed tumors (hot) and STING in non-flammable tumors (cold). iTeos Therapeutics’ competitive edge is in the design of best-in-class cancer immunotherapies by the combination of expertise in drug discovery, translational tumor immunology and early clinical trial design. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets.

iTeos Therapeutics is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development)

Contact: Michel Detheux
EOLE building
Rue des Frères Wright 29/3,
B-6041 Gosselies.